Immunotherapy before targeted therapy improves survival in advanced melanoma

Researchers reported a 20 percent advantage in the two-year overall survival rate for subjects with advanced melanoma and a mutation in the BRAF gene, specifically a BRAF V600 mutation, who were initially treated with immunotherapy (72 percent survival rate) compared with subjects initially treated with targeted therapies (52 percent survival rate). The findings from the DREAMseq trial were published on September 28, 2022 in […]